Immunotherapy

AUSTIN, Texas, August 12, 2026 Natera, Inc. announced a new collaboration with Kupando Therapeutics to support a Phase 1...

MILLBRAE, Calif., August 11, 2026 Eikon Therapeutics announced the selection of a 0.60 mg/m² dose of EIK1001 for patients...

OCALA, Fla., August 10, 2026 AIM ImmunoTech Inc. reported its second-quarter 2026 financial results and highlighted continued progress in...

San Diego, California, USA, August 8, 2026 Neurocrine Biosciences, Inc. has initiated a Phase 1 first-in-human clinical study evaluating...

Toronto, Ontario, Canada, August 8, 2026 Regeneron Canada Company announced that Health Canada has approved Libtayo® (cemiplimab for injection)...

LUND, Sweden, August 7, 2026 BioInvent International AB announced that the U.S. Food and Drug Administration (FDA) has granted...

NEW YORK, August 6, 2026 MiNK Therapeutics announced that it will report its second-quarter 2026 financial results before U.S....

NANJING, China, August 4, 2026 Leads Biolabs announced that its partner Oblenio Bio, a company jointly established with Aditum...

NANJING, China, August 6, 2026 Leads Biolabs announced that its Phase II clinical study evaluating Opamtistomig (LBL-024) in combination...

BOSTON, Aug. 4, 2026 CervoMed Inc. announced that its investigational oral therapy neflamapimod has been granted an Innovation Passport...